Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy

被引:14
作者
Awasthi, Niranjan [1 ,3 ]
Schwarz, Margaret A. [2 ]
Schwarz, Roderich E. [1 ,3 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
关键词
Pancreatic cancer; EMAP II; Doxorubicin; Docetaxel; Gemcitabine; Combination therapy; ACTIVATING POLYPEPTIDE-II; PHASE-II; PLUS GEMCITABINE; ENDOTHELIAL-CELLS; TRIAL; CISPLATIN; ADENOCARCINOMA; SURVIVAL; GROWTH; ANGIOGENESIS;
D O I
10.1007/s00280-010-1514-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gemcitabine has limited benefits as single agent or in combination for pancreatic ductal adenocarcinoma (PDAC). Endothelial monocyte-activating polypeptide II (EMAP) enhances gemcitabine effects in PDAC. We evaluated the combination effects of EMAP, doxorubicin, and docetaxel in experimental PDAC. Cell proliferation, protein expression, and apoptosis were analyzed by WST-1 assay, Western blotting, and FACS analysis. Tumor growth and survival experiments were performed in murine xenografts. PDAC cell proliferation in vitro was not affected by EMAP, compared to a small inhibition through doxorubicin, docetaxel, and gemcitabine. EMAP addition to these agents did not increase the antiproliferative effects. In endothelial cells, EMAP, doxorubicin, docetaxel, and gemcitabine all had antiproliferative effects. Addition of EMAP to these cytotoxic agents had additive effects. In PDAC cells, no agent induced measurable apoptosis, whereas in endothelial cells, all agents either alone or in combination did. Doxorubicin, docetaxel, gemcitabine, and EMAP all decreased tumor growth. EMAP addition increased inhibitory effects of docetaxel and gemcitabine, but not of doxorubicin. However, compared to controls (median survival: 17 days), EMAP (14 days) had no survival benefit, while docetaxel (29 days), gemcitabine (25 days), and docetaxel followed by gemcitabine sequence (37 days) extended animal survival. Addition of EMAP to docetaxel (35 days), gemcitabine (28 days), and docetaxel gemcitabine sequence (41 days) extended the survival. Doxorubicin effects were not enhanced by EMAP. The antiendothelial combination therapy benefit through EMAP is not limited to gemcitabine and may facilitate the development of more effective alternative cytotoxic therapy strategies against PDAC.
引用
收藏
页码:571 / 582
页数:12
相关论文
共 38 条
[1]   Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling [J].
Awasthi, Niranjan ;
Schwarz, Margaret A. ;
Verma, Varun ;
Cappiello, Clint ;
Schwarz, Roderich E. .
LABORATORY INVESTIGATION, 2009, 89 (01) :38-46
[2]   Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II) [J].
Berger, AC ;
Alexander, HR ;
Wu, PC ;
Tang, GQ ;
Gnant, MFX ;
Mixon, A ;
Turner, ES ;
Libutti, SK .
CYTOKINE, 2000, 12 (07) :992-1000
[3]   Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis [J].
Berger, AC ;
Alexander, HR ;
Tang, GQ ;
Wu, PS ;
Hewitt, SM ;
Turner, E ;
Kruger, E ;
Figg, WD ;
Grove, A ;
Kohn, E ;
Stern, D ;
Libutti, SK .
MICROVASCULAR RESEARCH, 2000, 60 (01) :70-80
[4]  
Bergman AM, 1996, CLIN CANCER RES, V2, P521
[5]   Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J].
Berlin, JD ;
Catalano, P ;
Thomas, JP ;
Kugler, JW ;
Haller, DG ;
Benson, AB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3270-3275
[6]   Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer [J].
Boeck, S. ;
Hoehler, T. ;
Seipelt, G. ;
Mahlberg, R. ;
Wein, A. ;
Hochhaus, A. ;
Boeck, H. -P. ;
Schmid, B. ;
Kettner, E. ;
Stauchlo, M. ;
Lordick, F. ;
Ko, Y. ;
Geissler, M. ;
Schoppmeyer, K. ;
Kojouharoff, G. ;
Golf, A. ;
Neugebauer, S. ;
Heinemann, V. .
ANNALS OF ONCOLOGY, 2008, 19 (02) :340-347
[7]   A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].
Bramhall, SR ;
Schulz, J ;
Nemunaitis, J ;
Brown, PD ;
Baillet, M ;
Buckels, JAC .
BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167
[8]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[9]   Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-α [J].
Crippa, Luca ;
Gasparri, Anna ;
Sacchi, Angelina ;
Ferrero, Elisabetta ;
Curnis, Flavio ;
Corti, Angelo .
CANCER RESEARCH, 2008, 68 (04) :1154-1161
[10]   Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma - Results of a phase II trial [J].
Dragovich, Tomislav ;
Burris, Howard, III ;
Loehrer, Patrick ;
Von Hoff, Daniel D. ;
Chow, Sherry ;
Stratton, Steven ;
Green, Sylvan ;
Obregon, Yrma ;
Alvarez, Irene ;
Gordon, Michael .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (02) :157-162